Hyperlipidemia in pediatric kidney transplant recipients treated with cyclosporine

被引:0
|
作者
Blanche M. Chavers
Maria Hårdstedt
Kristen J. Gillingham
机构
[1] University of Minnesota,Department of Pediatrics
[2] University of Minnesota,Department of Surgery
[3] University of Minnesota,Department of Pediatrics
来源
Pediatric Nephrology | 2003年 / 18卷
关键词
Hypercholesterolemia; Hypertriglyceridemia; Transplantation; Prevalence;
D O I
暂无
中图分类号
学科分类号
摘要
Hyperlipidemia is a risk factor for cardiovascular disease in adult kidney transplant (Tx) recipients. We sought to determine the prevalence of, and the risk factors associated with, hyperlipidemia in pediatric kidney Tx recipients on cyclosporine (CsA). We identified 59 patients (mean age 8.2±5.7 years) transplanted between 1 January 1991 and 31 December 1993. Pre Tx, 34% had elevated total cholesterol [TC >200 mg/dl (5.17 mmol/l)]; 54% had elevated triglycerides [TG >200 mg/dl (2.26 mmol/L)]. Mean TG was higher pre Tx in dialysis (versus nondialysis) patients: 306 mg/dl (3.46 mmol/l) versus 228 mg/dl (2.58 mmol/l) (P=0.04). Mean TC was higher in peritoneal dialysis than hemodialysis patients: 222 mg/dl (5.74 mmol/l) versus 169 mg/dl (4.37 mmol/l) (P=0.03). Pre Tx and 3-year values correlated (TC, r=0.49, P=0.0008; TG, r=0.41, P=0.001); 3- and 5-year TC values correlated (r=0.57, P=0.003). At 5 years post Tx, 41% of the recipients had elevated TC; 14% had elevated TG. Recipients with elevated TC had higher mean CsA concentrations at 1 year post Tx (P=0.03). Recipients with elevated TG tended to receive more prednisone (P=0.06). At 5 years post Tx, recipients had a high prevalence of hyperlipidemia. The identification and treatment of hyperlipidemia should be included in pediatric kidney Tx protocols.
引用
收藏
页码:565 / 569
页数:4
相关论文
共 50 条
  • [1] Hyperlipidemia in pediatric kidney transplant recipients treated with cyclosporine
    Chavers, BM
    Hårdstedt, M
    Gillingham, KJ
    PEDIATRIC NEPHROLOGY, 2003, 18 (06) : 565 - 569
  • [2] Kidney function in cyclosporine-treated pediatric heart transplant recipients
    Laine, J
    Jalanko, H
    LEijala, M
    Sairanen, H
    Holmberg, C
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1997, 16 (12): : 1217 - 1224
  • [3] LOVASTATIN TREATMENT OF HYPERLIPIDEMIA IN KIDNEY-TRANSPLANT RECIPIENTS ON CYCLOSPORINE IMMUNOSUPPRESSION
    KANDUS, A
    KOVAC, D
    KOSELJ, M
    KVEDER, R
    BREN, AF
    TRANSPLANTATION PROCEEDINGS, 1994, 26 (05) : 2642 - 2643
  • [5] Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients
    Mariano Ferraresso
    Luciana Ghio
    Alberto Edefonti
    Rosanna Garavaglia
    Luisa Berardinelli
    Pediatric Nephrology, 2002, 17 : 664 - 667
  • [6] Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients
    Ferraresso, M
    Ghio, L
    Edefonti, A
    Garavaglia, R
    Berardinelli, L
    PEDIATRIC NEPHROLOGY, 2002, 17 (08) : 664 - 667
  • [7] ANTITUBERCULOUS DRUGS IN KIDNEY-TRANSPLANT RECIPIENTS TREATED WITH CYCLOSPORINE
    PESCHKE, B
    ERNST, W
    GOSSMANN, J
    KACHEL, HG
    SCHOEPPE, W
    SCHEUERMANN, EH
    TRANSPLANTATION, 1993, 56 (01) : 236 - 238
  • [8] Kidney function in cyclosporine-treated paediatric pulmonary transplant recipients
    Tsimaratos, M
    Viard, L
    Kreitmann, B
    Remediani, C
    Picon, G
    Camboulives, J
    Sarles, J
    Metras, D
    TRANSPLANTATION, 2000, 69 (10) : 2055 - 2059
  • [9] CYCLOSPORINE PHARMACOKINETICS IN PEDIATRIC TRANSPLANT RECIPIENTS
    WANDSTRAT, TL
    SCHROEDER, TJ
    MYRE, SA
    THERAPEUTIC DRUG MONITORING, 1989, 11 (05) : 493 - 496
  • [10] HYPERLIPIDEMIA IN PEDIATRIC LIVER-TRANSPLANT RECIPIENTS
    MASCARENHAS, MR
    LINDNER, MA
    KAMANI, N
    WATKINS, JB
    PEDIATRIC RESEARCH, 1989, 25 (04) : A119 - A119